The estimated Net Worth of Ricardo Dolmetsch is at least $2.11 Million dollars as of 18 September 2023. Dr Dolmetsch owns over 5,841 units of uniQure N.V stock worth over $893,820 and over the last 4 years he sold QURE stock worth over $590,556. In addition, he makes $626,146 as Pres of R&D at uniQure N.V.
Dr has made over 6 trades of the uniQure N.V stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 5,841 units of QURE stock worth $43,574 on 18 September 2023.
The largest trade he's ever made was selling 8,603 units of uniQure N.V stock on 16 September 2021 worth over $319,171. On average, Dr trades about 2,161 units every 61 days since 2020. As of 18 September 2023 he still owns at least 163,404 units of uniQure N.V stock.
You can see the complete history of Dr Dolmetsch stock trades at the bottom of the page.
Dr. Ricardo Dolmetsch Ph.D. is the Pres of R&D at uniQure N.V.
As the Pres of R&D of uniQure N.V, the total compensation of Dr D at uniQure N.V is $626,146. There are 6 executives at uniQure N.V getting paid more, with Matthew Kapusta having the highest compensation of $4,719,960.
Dr D is 52, he's been the Pres of R&D of uniQure N.V since . There are 10 older and 4 younger executives at uniQure N.V. The oldest executive at uniQure N.V. is Jack Kaye, 76, who is the Non-Executive Independent Director.
Ricardo's mailing address filed with the SEC is C/O UNIQURE, N.V., PAASHEUVELWEG 25A, AMSTERDAM, P7, 11058BP.
Over the last 8 years, insiders at uniQure N.V have traded over $35,572,573 worth of uniQure N.V stock. The most active insiders traders include Deventer Sander Van, Paula Soteropoulos und William Lewis. On average, uniQure N.V executives and independent directors trade stock every 14 days with the average trade being worth of $37,634. The most recent stock trade was executed by Walid Abi Saab on 26 June 2024, trading 1,447 units of QURE stock currently worth $6,309.
uniqure is delivering on the promise of gene therapy - single treatments with potentially curative results. we are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.
uniQure N.V executives and other stock owners filed with the SEC include: